ASRS 2023: 2-year data on the PHOTON study of 8 milligrams of aflibercept for diabetic macular oedema (DME)

News
Video

Diana Do, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington, to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

At the 2023 ASRS meeting in Seattle, Washington, Diana Do, MD joined our team to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Diana Do, MD:

Hi, I'm Dr Diana Do, professor of ophthalmology and vice chair of clinical affairs at the Byers Eye Institute at Stanford University. Today, I had the pleasure of delivering the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

The key take home points are that 8 milligrams of aflibercept dosed every 12 weeks or every 16 Weeks was non-inferior to 2 milligrams of aflibercept given every 8 weeks, and these benefits were sustained through 2 years of follow up. In addition, it's remarkable that those eyes randomised to the 8 milligram dosing group were able to maintain dosing intervals of 12 weeks and 16 weeks for the vast majority of patients in the study. In fact, 89 percent of 8 milligram-treated eyes maintained 12 weeks or longer dosing intervals through 2 years. And at the last interval of dosing. Approximately 27 percent of subjects are able to be dosed at 24 weeks. In terms of safety, 8 milligrams of aflibercept had very low rates of intraocular inflammation, and the safety was comparable to that of 2 milligrams of aflibercept. In summary, 8 milligrams of aflibercept provided improved visual acuity outcomes and reductions in retinal thickness that were sustained through 2 years while decreasing the burden of frequent injections.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.